Japanese real-world study of sequential nivolumab and ipilimumab treament in melanoma.
Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal
/ administration & dosage
Antineoplastic Agents, Immunological
/ administration & dosage
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Drug Administration Schedule
Female
Humans
Ipilimumab
/ administration & dosage
Japan
Male
Melanoma
/ drug therapy
Middle Aged
Nivolumab
/ administration & dosage
Retrospective Studies
Skin Neoplasms
/ drug therapy
Japanese
ipilimumab
melanoma
nivolumab
sequential therapy
Journal
The Journal of dermatology
ISSN: 1346-8138
Titre abrégé: J Dermatol
Pays: England
ID NLM: 7600545
Informations de publication
Date de publication:
Nov 2019
Nov 2019
Historique:
received:
17
05
2019
accepted:
08
08
2019
pubmed:
19
9
2019
medline:
14
4
2020
entrez:
19
9
2019
Statut:
ppublish
Résumé
To describe the treatment patterns of nivolumab and ipilimumab in Japan, a retrospective observational study was conducted in melanoma patients who received nivolumab and ipilimumab sequentially. Patients who received nivolumab and ipilimumab in combination were excluded from this study. Efficacy was evaluated by the Response Evaluation Criteria in Solid Tumors (RECIST) in terms of the overall response rate (ORR), progression-free survival (PFS), and disease control rate (DCR). Overall survival (OS) was also evaluated. Safety was assessed by the Common Terminology Criteria for Adverse Events (CTCAE). The treatment for all 68 patients enrolled involved switching from nivolumab to ipilimumab in 61 patients and switching from ipilimumab to nivolumab in seven patients. Switching occurred because of progressive disease in 55 patients and adverse events in eight patients. The median number of ipilimumab doses was three. Ipilimumab treatment achieved an ORR and DCR of 4.9% and 21.3%, respectively, and the median OS from start of ipilimumab was 7.0 months. During the study period, no new safety signals were noted. Independent factors which were indicative of poor prognosis for PFS were high neutrophil-to-lymphocyte ratio (NLR) and high C-reactive protein (CRP) levels before ipilimumab treatment. An evaluation over a washout period indicated that no significant relationship existed with efficacy or safety. For the sequential administration of nivolumab and ipilimumab in Japanese melanoma patients, switch from nivolumab to ipilimumab was common, and the major reason for switching was progressive disease. The major prognostic factors for ipilimumab PFS after nivolumab were NLR and CRP before ipilimumab treatment.
Identifiants
pubmed: 31531895
doi: 10.1111/1346-8138.15073
doi:
Substances chimiques
Antibodies, Monoclonal
0
Antineoplastic Agents, Immunological
0
Ipilimumab
0
Nivolumab
31YO63LBSN
Types de publication
Journal Article
Multicenter Study
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
947-955Subventions
Organisme : Bristol-Myers Squibb
Organisme : Ono Pharmaceutical Co., Ltd.
Informations de copyright
© 2019 The Authors. The Journal of Dermatology published by John Wiley & Sons Australia, Ltd on behalf of Japanese Dermatological Association.
Références
Fujisawa Y , Otsuka F . Epidemiologic survey of malignant skin tumors - international comparison between Japan and foreign countries. Nippon Rinsho 2013; 71(suppl 4): 7-12 (In Japanese).
Nishi M . Epidemiology of skin cancer in Japan. J Tumor 2016; 4: 369-373.
Guy GP Jr , Thomas CC , Thompson T et al. Vital signs: melanoma incidence and mortality trends and projections - United States. MMWR Morb Mortal Wkly Rep 2015; 64: 591-596.
Kiyohara Y , Uhara H , Ito Y , Matsumoto N , Tsuchida T , Yamazaki N . Safety and efficacy of nivolumab in Japanese patients with malignant melanoma: an interim analysis of a postmarketing surveillance. J Dermatol 2018; 45: 408-415.
Fujisawa Y , Yoshikawa S , Minagawa A et al. Clinical and histopathological characteristics and survival analysis of 4594 Japanese patients with melanoma. Cancer Med 2019; 8: 2146-2156.
Tomizuka T , Namikawa K , Higashi T . Characteristics of melanoma in Japan: a nationwide registry analysis 2011-2013. Melanoma Res 2017; 27: 492-497.
Fujisawa Y . Epidemiology of the melanoma. Current Ther 2016; 34: 326-331 (In Japanese).
Sakaizawa K , Ashida A , Uchiyama A et al. Clinical characteristics associated with BRAF, NRAS and KIT mutations in Japanese melanoma patients. J Dermatol Sci 2015; 80: 33-37.
Yamazaki N , Tanaka R , Tsutsumida A et al. BRAF V600 mutations and pathological features in Japanese melanoma patients. Melanoma Res 2015; 25: 9-14.
Pardoll DM . The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12: 252-264.
Wolchok JD , Kluger H , Callahan MK et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013; 369: 122-133.
Postow MA , Chesney J , Pavlick AC et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 2015; 372: 2006-2017.
Larkin J , Chiarion-Sileni V , Gonzalez R et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015; 373: 23-34.
Weber JS , Gibney G , Sullivan R et al. Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial. Lancet Oncol 2016; 17: 943-955.
Whitman ED , Liu FX , Cao X , Diede SJ , Haiderali A , Abernethy AP . Treatment patterns and outcomes for patients with advanced melanoma in US oncology clinical practices. Future Oncol 2019; 15: 459-471.
Yamazaki N , Kiyohara Y , Uhara H et al. Guide of the pharmacotherapy for melanoma. Skin Cancer 2017; 32: 1-5 (In Japanese).
Fujisawa Y , Yoshino K , Otsuka A et al. Retrospective study of advanced melanoma patients treated with ipilimumab after nivolumab: analysis of 60 Japanese patients. J Dermatol Sci 2018; 89: 60-66.
Zimmer L , Apuri L , Eroglu Z et al. Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma. Eur J Cancer 2017; 75: 47-55.
Yamazaki N , Kiyohara Y , Uhara H et al. Cytokine biomarkers to predict antitumor responses to nivolumab suggested in a phase 2 study for advanced melanoma. Cancer Sci 2017; 108: 1022-1031.
Yamazaki N , Kiyohara Y , Uhara H et al. Efficacy and safety of nivolumab in Japanese patients with previously untreated advanced melanoma: a phase II study. Cancer Sci 2017; 108: 1223-1230.
Yamazaki N , Kiyohara Y , Uhara H et al. Phase II study of ipilimumab monotherapy in Japanese patients with advanced melanoma. Cancer Chemother Pharmacol 2015; 76: 997-1004.
Mohr P , Ascierto P , Arance A et al. Real-world treatment patterns and outcomes among metastatic cutaneous melanoma patients treated with ipilimumab. J Eur Acad Dermatol Venereol 2018; 32: 962-971.
Russi A , Damuzzo V , Chiumente M et al. Ipilimumab in real-world clinical practice: efficacy and safety data from a multicenter observational study. J Chemother 2017; 29: 245-251.
Hodi FS , O'Day SJ , McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-723.
Robert C , Thomas L , Bondarenko I et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364: 2517-2526.
Nakamura Y , Kitano S , Takahashi A et al. Nivolumab for advanced melanoma: pretreatment prognostic factors and early outcome markers during therapy. Oncotarget 2016; 7: 77404-77415.
Ferrucci PF , Gandini S , Battaglia A . Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients. Br J Cancer 2015; 112: 1904-1910.
Muto Y , Kitano S , Tsutsumida A et al. Investigation of clinical factors associated with longer overall survival in advanced melanoma patients treated with sequential ipilimumab. J Dermatol 2019; 46: 498-506.